CytomX
cytomx.com
Health Care
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
CytomX. CytomX is a different kind of clinical-stage biopharmaceutical company – intent on revolutionizing the way we treat cancer. Our distinctive Probody® therapeutics are progressing through the clinic with the promise of unlocking the full potential of more potent, less toxic cancer medications.
News
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC -- Potential Varseta-M monotherapy registrati...
Read more
Report
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its research collaboration with Regeneron to develop next-gen conditionally-activated bispecific cancer therapies. By combining CytomX
Read more
Report
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Thursday,
Read more
Report
Varsetatug masetecan (CX-2051): Unlocking EpCAM as a Cancer Target via a Masked EPCAM-Directed Topo1 ADC
Sean McCarthy, D.Phil., CEO and Chairman
Read more
Report
Pharmacodynamic and Pharmacokinetic Activity of CX-801, a Masked IFNα2b PROBODY Cytokine, in Patients with Advanced Melanoma
Benjamin Povinelli, Shannon Tsai, Kakali Dhar, Cathrine Leonowens, Stuart Johnston, Olga Vasiljeva, Madan Paidhungat, Yu-Waye Chu, Marcia Belvin, John M. Kirkwood, Yana G. Najjar, Monika Vainorius, Dylan Daniel; Poster presented at the Society for Immunot
Read more
Report
CX-908, a PROBODY T Cell Engager Targeting CDH3 and CD3, Induces Tumor Regressions and Improves the Therapeutic Window in Preclinical Studies
Erwan Le Scolan, Lauren Kadavy, Leila M. Boustany, Clayton White, Tiffany Tse, Sayantan Mitra, Nicole Lapuyade, Vijit Dalal, Kai-Wen Cheng, Anna F. Nguyen, Conner Bardine, Michael B. Winter, Vahideh Vakil, Sean McAllister, Robert T. Dunn, II, Vangipuram R
Read more
Report
Show more news